GLF
NERV icon

Groupe la Francaise’s Minerva Neurosciences NERV Stock Holding History

Groupe la Francaise’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-337
Closed -$603 – 663
2025
Q3 		$603 Buy
+337
New +$689 ﹤0.01% 748

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Groupe la Francaise's NERV Position: Q4 2025 in Review

Groupe la Francaise sold out of Minerva Neurosciences (NERV) in Q4 2025, closing a stake of 337 shares — an estimated $603 sold.

Groupe la Francaise first reported a position in NERV in Q3 2025 and held it in 1 quarter. The position peaked at $603 in Q3 2025. 33 funds tracked by Wall St. Rank hold NERV as of Q4 2025.

  • Groupe la Francaise reported no remaining Minerva Neurosciences position as of Q4 2025 after selling out during the quarter.
  • Groupe la Francaise sold 337 Minerva Neurosciences shares in Q4 2025, an estimated $603.
  • Groupe la Francaise first reported a position in Minerva Neurosciences in Q3 2025 and held it in 1 quarter.
  • Groupe la Francaise's Minerva Neurosciences position peaked at $603 in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.